blocking antibody


Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

blocking antibody

[¦bläk·iŋ ¦ant·i‚bäd·e]
(immunology)
Antibody that inhibits the reaction between antigen and other antibodies or sensitized T lymphocytes.
References in periodicals archive ?
Since the NF-[kappa]B pathway can be activated by TLR4, we next preincubated PDL cells with an anti-TLR4 blocking antibody. Our experiments showed that the initial stimulatory effect of F.
In this study, we showed that co-culturing of the B7-H1-expressing A549 cells with T cells in vitro resulted in inhibition of T-cell proliferation, and the addition of B7-H1 blocking antibody markedly relieved the inhibition of T-cell proliferation.
These data showed that in SW620 cells, Pcy was able to activate the Fas-receptor after blocking TRAIL-death receptors, explaining, therefore, the enhanced apoptosis observed when SW620 cells were exposed to the DR4/DR5 blocking antibody.
"All we did was delay the onset and reduce the severity,' says Banerjee, who adds that the next step will be to increase the dose of blocking antibody.
FDA has further acknowledged that conduct of a randomized Phase 3 trial may not be feasible in its intended population of advanced melanoma patients who have been treated with at least one systemic therapy including a PD-1 blocking antibody and if BRAF V600 mutation positive, a BRAF inhibitor or BRAF inhibitor with MEK inhibitor and is not required for initial registration of lifileucel.
ATOR-1015 is primarily designed for combination therapy with a PD-1 blocking antibody and the potential of this approach is supported with preclinical data reporting enhanced anti-tumour effect of ATOR-1015 in combination with an anti-PD -1 antibody, as compared to anti-PD-1 monotherapy.
Nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, has been approved as a single agent for the first-line treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma, the manufacturer has announced.
BAVENCIO (avelumab) is a human programmed death ligand-1 (PD-L1) blocking antibody indicated in the US for locally advanced or metastatic urothelial carcinoma who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy, concluded the companies.
They showed that addition of a blocking antibody against IL-34 to SF conditioned media reduced the migration of human mononuclear cells in a dose-dependent manner.
The efficiency of this HAMA blocking antibody in CARDIAC T Quantitative has been repeatedly tested with heparinized blood samples where plasma was exchanged by two commercial HAMA sera (cat.